{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:01:38Z","timestamp":1773226898207,"version":"3.50.1"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104172","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T22:40:18Z","timestamp":1662763218000},"page":"104172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-5018","authenticated-orcid":false,"given":"Enoch","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Haag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M.","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0244-0005","authenticated-orcid":false,"given":"Michelle","family":"Demory Beckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9017","key":"10.1016\/j.msard.2022.104172_bib0001","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(96)90807-7","article-title":"Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group","volume":"347","author":"Sadovnick","year":"1996","journal-title":"Lancet"},{"issue":"3\u20134","key":"10.1016\/j.msard.2022.104172_bib0002","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104172_bib0003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1673-5374.245462","article-title":"The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging","volume":"14","author":"Guan","year":"2019","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jfmk3010013","article-title":"Insights into the role of neuroinflammation in the pathogenesis of multiple sclerosis","volume":"3","author":"Al-Badri","year":"2018","journal-title":"J. Funct. Morphol. Kinesiol."},{"issue":"9","key":"10.1016\/j.msard.2022.104172_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis. Review","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0007","first-page":"1","article-title":"Multiple Sclerosis: pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncpneuro0154","article-title":"Immunopathogenesis and immunotherapy of multiple sclerosis","volume":"2","author":"Hemmer","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/brainsci7070078","article-title":"Multiple Sclerosis: immunopathology and Treatment Update","volume":"7","author":"Dargahi","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2022.104172_bib0010","series-title":"Current Diagnosis and Treatment in Neurology. New York","article-title":"Multiple sclerosis","author":"Cree","year":"2007"},{"issue":"11","key":"10.1016\/j.msard.2022.104172_bib0011","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/1352458509107010","article-title":"Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients","volume":"15","author":"Smestad","year":"2009","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2022.104172_bib0012","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/ene.12130","article-title":"Hospital admission due to infections in multiple sclerosis patients","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur. J. Neurol."},{"issue":"Suppl 201","key":"10.1016\/j.msard.2022.104172_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ane.12835","article-title":"Infections in patients with multiple sclerosis: implications for disease-modifying therapy","volume":"136","author":"Celius","year":"2017","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7224\/1537-2073.2014-035","article-title":"Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans","volume":"17","author":"Nelson","year":"2015","journal-title":"Int. J. MS Care"},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0015","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","article-title":"Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England","volume":"77","author":"Palladino","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.104172_bib0016","unstructured":"FDA Approves First COVID-19 Vaccine. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine. Accessed March 15, 2022."},{"key":"10.1016\/j.msard.2022.104172_bib0017","series-title":"FDA Takes Key Action By Approving Second COVID-19 Vaccine","year":"2022"},{"issue":"9","key":"10.1016\/j.msard.2022.104172_bib0018","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104172_bib0019","first-page":"362","article-title":"Risk of SARS-CoV-2 infection and clinical outcomes in multiple sclerosis patients in La Rioja (Spain): riesgo de infecci\u00f3n por SARS-CoV-2 y resultados cl\u00ednicos en pacientes con esclerosis m\u00faltiple en la Rioja (Espa\u00f1a)","volume":"155","author":"F","year":"2020","journal-title":"Med. Clin. (Engl. Ed)"},{"key":"10.1016\/j.msard.2022.104172_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000787","article-title":"Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders","volume":"7","author":"Fan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0022","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0023","doi-asserted-by":"crossref","first-page":"e1001","DOI":"10.1212\/NXI.0000000000001001","article-title":"COVID-19 Among Patients With Multiple Sclerosis: a Systematic Review","volume":"8","author":"Barzegar","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104172_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.104172_bib0026","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry","author":"Spelman","year":"2021","journal-title":"Mult. Scler."},{"issue":"19","key":"10.1016\/j.msard.2022.104172_bib0027","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104172_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2022.104172_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0030","doi-asserted-by":"crossref","first-page":"e761","DOI":"10.1212\/NXI.0000000000000761","article-title":"Bar-Or A. COVID-19 and MS disease-modifying therapies","volume":"7","author":"Berger","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0031","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3947\/ic.2021.0028","article-title":"Effects of Interferon Beta in COVID-19 adult patients: systematic Review","volume":"53","author":"Sosa","year":"2021","journal-title":"Infect. Chemother."},{"issue":"9","key":"10.1016\/j.msard.2022.104172_bib0032","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104172_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2022.104172_bib0034","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.104172_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102788","article-title":"Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States","volume":"49","author":"Ehde","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104172_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102880","article-title":"Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients","volume":"51","author":"Serrazina","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0037","first-page":"e1104","article-title":"COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis","volume":"9","author":"FBS","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0038","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler."},{"issue":"27","key":"10.1016\/j.msard.2022.104172_bib0039","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2022.104172_bib0040","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1080\/21645515.2021.1928463","article-title":"Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient","volume":"17","author":"Etemadifar","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.msard.2022.104172_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577755","article-title":"Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"361","author":"Fujimori","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0042","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00415-021-10648-w","article-title":"First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"269","author":"Havla","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104172_bib0043","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0044","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.26251","article-title":"COVID-19 Vaccine Response in People with Multiple Sclerosis","volume":"91","author":"Tallantyre","year":"2022","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function","volume":"7","author":"Sabatino","year":"2022","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.msard.2022.104172_bib0046","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2022.104172_bib0047","article-title":"SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab [published online ahead of print, 2022 Mar 4]","author":"Brill","year":"2022","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0048","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2022.104172_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120155","article-title":"COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose","volume":"434","author":"Dreyer-Alster","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104172_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103729","article-title":"Persistently reduced humoral and sustained cellular immune response from first to third SARS-COV-2 mrna vaccination in anti-cd20-treated multiple sclerosis patients","author":"Bajwa","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2022.104172_bib0051","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/vaccines9121470","article-title":"Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis","volume":"9","author":"Achtnichts","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0052","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/vaccines10020341","article-title":"SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: protective Humoral Immune Responses May Develop after the Preferred Third Shot","volume":"10","author":"Achtnichts","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.msard.2022.104172_bib0053","unstructured":"Swiss Multiple Sclerosis Society. Startseite. https:\/\/www.multiplesklerose.ch\/de\/aktuelles\/detail\/anti-sars-cov2-impfung-und-multiple-sklerose\/. Published March 7, 2022. Accessed March 15, 2022."},{"issue":"24","key":"10.1016\/j.msard.2022.104172_bib0054","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.msard.2022.104172_bib0055","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0056","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2021.7382","article-title":"Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine","volume":"182","author":"Patalon","year":"2022","journal-title":"JAMA Intern. Med."},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0057","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/vaccines9070773","article-title":"Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations","volume":"9","author":"Cabreira","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0058","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002036","article-title":"Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients","volume":"8","author":"Schietzel","year":"2022","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.msard.2022.104172_bib0059","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis","volume":"78","author":"Disanto","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0060","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0061","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"15","key":"10.1016\/j.msard.2022.104172_bib0062","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1212\/WNL.0000000000012578","article-title":"COVID-19 and Vaccination in the Setting of Neurologic Disease: an Emerging Issue in Neurology","volume":"97","author":"Marsh","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104172_bib0063","unstructured":"Covid-19 Vaccine Guidance for People Living with MS. National Multiple Sclerosis Society. https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/multiple-sclerosis-and-coronavirus\/covid-19-vaccine-guidance. Accessed March 14, 2022."},{"key":"10.1016\/j.msard.2022.104172_bib0064","unstructured":"Disease Modifying Therapy Guidelines During COVID-19. National Multiple Sclerosis Society. https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/multiple-sclerosis-and-coronavirus\/ms-treatment-guidelines-during-coronavirus. Accessed March 14, 2022."},{"key":"10.1016\/j.msard.2022.104172_bib0065","article-title":"EAN Joint Session at 37th ECTRIMS Congress to Focus on Vaccination and Treatment Guidelines for People with Multiple Sclerosis","author":"Lee","year":"2022","journal-title":"eanpages"},{"key":"10.1016\/j.msard.2022.104172_bib0066","article-title":"Updated Global Advice","year":"2021","journal-title":"MS Int. Federation"},{"key":"10.1016\/j.msard.2022.104172_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102698","article-title":"Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: a Systematic Review and Meta-Analysis","volume":"48","author":"Nguyen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2022.104172_bib0068","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2022.104172_bib0069","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/135245859700300405","article-title":"Influenza virus vaccination of patients with multiple sclerosis","volume":"3","author":"Mokhtarian","year":"1997","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0071","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ene.12132","article-title":"Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"20","author":"Kim","year":"2013","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0072","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS Neurosci. Ther."},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0073","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1212\/WNL.56.7.938","article-title":"Influenza vaccination in MS: absence of T-cell response against white matter proteins","volume":"56","author":"Moriabadi","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0074","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1179\/1743132812Y.0000000059","article-title":"Humoral immune response to influenza vaccine in natalizumab-treated MS patients","volume":"34","author":"Vagberg","year":"2012","journal-title":"Neurol. Res."},{"issue":"11","key":"10.1016\/j.msard.2022.104172_bib0075","doi-asserted-by":"crossref","first-page":"e78532","DOI":"10.1371\/journal.pone.0078532","article-title":"Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNbeta-therapy","volume":"8","author":"Mehling","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0076","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","article-title":"Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients","volume":"69","author":"Mehling","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0077","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.msard.2022.104172_bib0078","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","article-title":"Hepatitis B virus infection: epidemiology and vaccination","volume":"28","author":"Shepard","year":"2006","journal-title":"Epidemiol. Rev."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2022.104172_bib0079","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(03)00152-1","article-title":"Hepatitis B vaccines","volume":"39","author":"Shouval","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.msard.2022.104172_bib0080","unstructured":"Hepatitis B., FAQs, Statistics, Data, & Guidelines. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/hepatitis\/hbv\/index.htm Published October 12, 2021. Accessed March 15, 2022."},{"issue":"8776","key":"10.1016\/j.msard.2022.104172_bib0081","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/0140-6736(91)92034-Y","article-title":"Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine","volume":"338","author":"Herroelen","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0082","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/WNL.53.2.396","article-title":"Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS?","volume":"53","author":"Tourbah","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0083","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.60.4.504","article-title":"Vaccinations and risk of central nervous system demyelinating diseases in adults","volume":"60","author":"DeStefano","year":"2003","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104172_bib0084","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archpedi.161.12.1176","article-title":"Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis","volume":"161","author":"Mikaeloff","year":"2007","journal-title":"Arch. Pediatr. Adolesc. Med."},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200102013440502","article-title":"Hepatitis B vaccination and the risk of multiple sclerosis","volume":"344","author":"Ascherio","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0086","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1212\/01.WNL.0000138433.61870.82","article-title":"Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study","volume":"63","author":"Hern\u00e1n","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0087","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccines in Multiple Sclerosis Study Group. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group","volume":"344","author":"Confavreux","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0088","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1080\/21645515.2018.1528835","article-title":"HBV vaccine and risk of developing multiple sclerosis: a systematic review and meta-analysis","volume":"17","author":"Sestili","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0089","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jfma.2019.10.012","article-title":"Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis","volume":"119","author":"Lu","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"issue":"2","key":"10.1016\/j.msard.2022.104172_bib0091","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1212\/NXI.0000000000000072","article-title":"Fatal acute liver failure with hepatitis B virus infection during nataluzimab treatment in multiple sclerosis","volume":"2","author":"Hillen","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0092","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy356","article-title":"Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis","volume":"6","author":"Ciardi","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"3","key":"10.1016\/j.msard.2022.104172_bib0093","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0609.2004.00375.x","article-title":"Hepatitis B virus reactivation and alemtuzumab therapy","volume":"74","author":"Iannitto","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.msard.2022.104172_bib0094","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.coviro.2019.01.002","article-title":"Successes and challenges for preventing measles, mumps and rubella by vaccination","volume":"34","author":"Bankamp","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.msard.2022.104172_bib0095","series-title":"MMR Vaccine. In: StatPearls. Treasure Island (FL)","author":"Bailey","year":"2021"},{"issue":"36","key":"10.1016\/j.msard.2022.104172_bib0096","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1016\/j.vaccine.2017.07.051","article-title":"MMR and MMRV vaccines","volume":"36","author":"Kowalzik","year":"2018","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.msard.2022.104172_bib0097","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/HAB-150289","article-title":"Frequency of viral infections and environmental factors in multiple sclerosis","volume":"24","author":"Eftekharian","year":"2016","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.msard.2022.104172_bib0098","article-title":"Unilateral Optic Neuritis: a Rare Complication after Measles-Mumps-Rubella Vac.cination in a 30-Year-Old Woman","author":"De Giacinto","year":"2016","journal-title":"Case Rep Ophthalmol Med"},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0099","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0404.1989.tb03904.x","article-title":"The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children","volume":"80","author":"Riikonen","year":"1989","journal-title":"Acta Neurol Scand"},{"issue":"7002","key":"10.1016\/j.msard.2022.104172_bib0100","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.311.7002.422a","article-title":"Transverse myelitis after measles, mumps, and rubella vaccine","volume":"311","author":"Joyce","year":"1995","journal-title":"BMJ"},{"issue":"9\u201310","key":"10.1016\/j.msard.2022.104172_bib0101","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1440-1754.2004.00470.x","article-title":"Transverse myelitis after measles and rubella vaccination","volume":"40","author":"Lim","year":"2004","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0102","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10072-003-0147-6","article-title":"Risk factors of multiple sclerosis: a case-control study","volume":"24","author":"Zorzon","year":"2003","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000201564","article-title":"Association of infectious mononucleosis with multiple sclerosis. A population-based study","volume":"32","author":"Ramagopalan","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0404.2008.01131.x","article-title":"Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations","volume":"119","author":"Ahlgren","year":"2009","journal-title":"Acta Neurol. Scand."},{"issue":"9","key":"10.1016\/j.msard.2022.104172_bib0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-009-9367-2","article-title":"A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk","volume":"24","author":"Ahlgren","year":"2009","journal-title":"Eur. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.msard.2022.104172_bib0106","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","article-title":"Immunizations and risk of multiple sclerosis: systematic review and meta-analysis","volume":"258","author":"Farez","year":"2011","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0107","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/practneurol-2020-002527","article-title":"Protecting people with multiple sclerosis through vaccination","volume":"20","author":"Reyes","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2022.104172_bib0108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.msard.2019.04.004","article-title":"Vukusic S; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Soci\u00e9t\u00e9 Francophone de la Scl\u00e9rose En Plaques (SFSEP). Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society","volume":"31","author":"Lebrun","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104172_bib0109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.msard.2022.104172_bib0110","unstructured":"Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/std\/statistics\/prevalence-2020-at-a-glance.htm. Published January 25, 2021. Accessed March 15, 2022."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1155\/2007\/591826","article-title":"International standard reagents for HPV detection","volume":"23","author":"Pagliusi","year":"2007","journal-title":"Dis Markers"},{"issue":"11","key":"10.1016\/j.msard.2022.104172_bib0112","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.msard.2022.104172_bib0113","article-title":"the Vaccine for HPV, and Cancers Caused By HPV","year":"2021","journal-title":"Centers for Disease Control and Prevention"},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0114","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines - A review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.msard.2022.104172_bib0115","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1080\/21645515.2017.1423155","article-title":"Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: a systematic review","volume":"14","author":"Meggiolaro","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.msard.2022.104172_bib0116","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0117","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"CNS demyelination and quadrivalent HPV vaccination","volume":"15","author":"Sutton","year":"2009","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0118","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2022.104172_bib0119","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J. Autoimmun."},{"issue":"8","key":"10.1016\/j.msard.2022.104172_bib0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10654-013-9830-y","article-title":"No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus","volume":"28","author":"Pellegrino","year":"2013","journal-title":"Eur. J. Epidemiol."},{"issue":"11","key":"10.1016\/j.msard.2022.104172_bib0121","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1177\/1352458518807088","article-title":"Warts and all: fingolimod and unusual HPV-associated lesions","volume":"25","author":"Triplett","year":"2019","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2022.104172_bib0122","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2011-10-388892","article-title":"Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice","volume":"119","author":"Lorvik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.msard.2022.104172_bib0123","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.msard.2018.04.018","article-title":"HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod","volume":"23","author":"Benedetti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104172_bib0124","series-title":"National Multiple Sclerosis Society","year":"2022"},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1055\/s-2005-925523","article-title":"Streptococcus pneumoniae: epidemiology, risk factors, and clinical features","volume":"26","author":"Ortqvist","year":"2005","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0126","first-page":"27","article-title":"A Review of Pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens","volume":"21","author":"Daniels","year":"2016","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.msard.2022.104172_bib0127","series-title":"Centers For Disease Control and Prevention","year":"2022"},{"issue":"14","key":"10.1016\/j.msard.2022.104172_bib0128","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2022.104172_bib0129","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"RR\u20137","key":"10.1016\/j.msard.2022.104172_bib0131","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm. Rep."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0132","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.msard.2022.104172_bib0133","series-title":"Centers For Disease Control and Prevention","year":"2021"},{"issue":"10","key":"10.1016\/j.msard.2022.104172_bib0134","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneurol.2011.131","article-title":"Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis","volume":"68","author":"Farez","year":"2011","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104172_bib0135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archneurol.2011.1519","article-title":"Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination","volume":"69","author":"Pool","year":"2012","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104172_bib0136","doi-asserted-by":"crossref","first-page":"e726","DOI":"10.1212\/NXI.0000000000000726","article-title":"Risk of MS relapse after yellow fever vaccination: a self-controlled case series","volume":"7","author":"Huttner","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"14","key":"10.1016\/j.msard.2022.104172_bib0137","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1177\/13524585211006372","article-title":"Multiple sclerosis: is there a risk of worsening after yellow fever vaccination?","volume":"27","author":"Papeix","year":"2021","journal-title":"Multiple Sclerosis J."},{"issue":"6","key":"10.1016\/j.msard.2022.104172_bib0138","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"23","key":"10.1016\/j.msard.2022.104172_bib0139","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.3390\/ijms20235985","article-title":"Fulminant MS reactivation following combined fingolimod cessation and yellow fever vaccination","volume":"20","author":"Rolfes","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:22Z","timestamp":1761901642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":139,"alternative-id":["S2211034822006770"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104172","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104172"}}